REFERENCES

TERMS & CONDITIONS – Magasil Braai Month – September 2026

1. The competition is open to South African residents aged 18 years or older. Employees of Gulf Drug Company (Pty) Ltd (“GDC”), their immediate family members, and anyone directly involved in the organisation or judging of the competition are not eligible to enter.

2. To enter the competition, participants must:

  • 1. Follow the official Magasil social media page;

  • 2. Tag one (1) friend in the comments; and

  • 3. Comment with their favourite food to braai.

3. The competition will run from 20 - 30 September 2026 as part of September Braai Month. Entries received after the closing date will not be accepted or considered.

4. A maximum of three (3) winners will be selected by GDC. Winners will be selected randomly from all valid entries received during the competition period. The winners will be selected and announced during the first week of October 2026 on the official Magasil social media page.

5. Each winner will receive one (1) braai set. Prizes will be allocated within 10 days of the winner announcement.

6. Winners will be notified via direct message on the relevant social media platform. Winners may also be acknowledged on Magasil social media, subject to their consent.

7. If a winner cannot be contacted or does not claim the prize within 7 days of notification, GDC reserves the right to withdraw the prize and select a replacement winner.

8. No entry is valid until it has successfully completed the validation process determined by GDC.

9. The prize is non-transferable, non-refundable and may not be exchanged for cash or any other item.

10. The decision of GDC regarding the selection of winners and interpretation of these Terms and Conditions is final. No correspondence or discussion will be entered into.

11. GDC reserves the right to disqualify any entry that does not comply with these Terms and Conditions or is deemed inappropriate, offensive, fraudulent, or otherwise invalid.

12. By entering the competition, participants agree to be bound by these Terms and Conditions.

13. Personal information provided by participants will be used solely for the purpose of administering the competition, contacting winners, and fulfilling prizes.

14. Personal information will not be shared with third parties without consent, unless required by law.

15. GDC reserves the right to amend, suspend, postpone, or cancel the competition at any time without prior notice should circumstances beyond its reasonable control make this necessary.

16. This competition is not sponsored, endorsed, administered by, or associated with Facebook, Instagram, or any other social media platform on which the competition may be hosted.

Applicant’s address and contact details

Gulf Drug Company (Pty) Ltd. 29 Scott Street, Waverley, Johannesburg, 2090, South Africa. Reg. No.: 1984/005793/07.

For full prescribing details refer to the approved patient information leaflet. Further information is available from Gulf Drug Company (Pty) Ltd. info@gulfdrug.co.za

Product composition:

Gastrointestinal / Digestive wellbeing

  • S2 Dicyclomine Co Gel 100 mL, 200 mL. Each 10 mL contains: Dicyclomine HCl 5 mg, compressed aluminium hydroxide gel 400 mg, light magnesium oxide 200 mg. Ref. nr: E1405 (Act 101/1965)

  • S0 De Witt’s Antacid Powder 100 g, 200 g. Each 2,5 g contains:  Sodium bicarbonate 1,2125 g, calcium carbonate 0,5 g, magnesium carbonate light 0,25 g, magnesium trisilicate 0,25 g, aluminium hydroxide gel 0,05 g. Reg. nr:  E/11.4.1/731

  • S0 Magasil 100 mL, 200 mL. Each 10 mL contains: Magnesium carbonate light 500 mg, magnesium trisilicate 500 mg, sodium bicarbonate 500 mg. Ref. nr: E1402 (Act 101/1965)

  • S0 Pectikon Suspension 100 mL. Each 30 mL contains: Kaolin light 6 g, apple pectin 450 mg. Ref. nr:  E1413 (Act 101/1965)

  • S0 Fybalax 10s, 30s. Each 4,6 g sachet contains: Ispaghula husk 95 % powder 3,69 g providing Ispaghula husk 3,5 g Category D Medicine: Discipline specific: D 33.8 Other. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

Pain, Fever & Inflammation

  • S0 S1 Painblok 2s, 10s, 20s, 24s, 100s, 1000s. Each tablet contains: Paracetamol 500 mg. Reg. nr: 27/2.7/0138. CONTAINS PARACETAMOL.

  • S0 Painblok Syrup (50 mL, 100 mL) Each 5 mL contains:  Paracetamol 120 mg Ref. nr:  B1454 (Act 101/1965). CONTAINS PARACETAMOL.

  • S0 Painblok Syrup Alcohol & Sugar Free (50 mL, 100 mL) Each 5 mL contains: Paracetamol 120 mg Reg. nr:  29/2.7/0208. CONTAINS PARACETAMOL.

  • Solarub 25 g, 500 g. S0. Each 100 g ointment contains: 10 g Gaultheria Procumbens (Wintergreen oil). Category D medicine: Discipline Specific. D33.6 Western Herbal Medicine. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S1 JP Paracetamol 500 mg 1000s. Each tablet contains: Paracetamol 500 mg. Reg. nr:  B/2.7/1644

  • S1 Von Paracetamol 500 mg 1000s Each tablet contains: Paracetamol 500 mg. Reg. nr:  B/2.7/1480

  • S0 Solex 14s. Each tablet contains: Aspirin 325 mg. Reg. nr:  P/2.8/70

  • S3 Roxifen 30s. Each capsule contains: Piroxicam 20 mg. Reg. nr: 27/3.1/0059

  • S0 Solarub Heatbalm 25 g, 100 g, 500 g. Each 100 g ointment contains: 10 g Gaultheria Procumbens (Wintergreen oil). Category D medicine:  Discipline Specific: D33.6 Western Herbal Medicine. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Gulf Aspirin 300 mg 14s, 1000s. Each tablet contains: Aspirin 300 mg. Ref. nr:  B1646 (Act 101/1965)

  • S2 DoxyCo 20s, 40s. Each tablet contains: Caffeine 30 mg, codeine phosphate 10 mg, doxylamine succinate 5 mg, paracetamol 450 mg. Reg. nr: 33/2.8/0098

  • S3 Gulf Indomethacin 25 1000s. Each capsule contains: Indomethacin 25 mg. Reg. nr: 27/3.1/0136

  • S3 Ibunate 200 mg 1000s. Each tablet contains: Ibuprofen 200 mg. Reg. nr: 29/3.1/0727

  • S3 Difen SR 100 (slow-release tablets). Each tablet contains Diclofenac Sodium 100 mg. Reg nr: 37/3.1/0641.

Renal & Diuretics

  • S3 Gulf Hydrochlorothiazide 25 100s. Each tablet contains: Hydrochlorothiazide 25 mg. Reg. nr:  41/18.1/0559

  • S0 De Witt’s K&B Pills 16s, 40s, 100s. Each tablet contains: Dry Buchu Extract 27,5 mg, Extract Uva Ursi 55 mg. Ref. nr:  H1642 (Act 101/1965)

Vitamins, Minerals & Supplements

  • S0 Gulf Ascorbic acid 250 mg 1000s. Each tablet contains: 250 mg of Ascorbic Acid (Vitamin C). Category D Medicine: Health Supplement: Vitamin D 34.11. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S1 Gulf Folic Acid 5 100s, 1000s. Each tablet contains: Folic acid 5 mg. Reg. nr: A40/22.2/0592

  • S1 Ferrous Sulphate Compound Tablets GDC 30s, 100s, 500s. Each tablet contains: Dried ferrous sulphate equivalent to FeSO4 170 mg, Copper sulphate 2,5 mg, Manganese sulphate monohydrate 2,5 mg. Ref. nr: H0825 (Act 101/1965)

  • S0 GDC Multivitamin Syrup 100mL. Each 5 mL syrup contains:  Vitamin A (from Vitamin A acetate) 2000 IU, Vitamin D3 (from Cholecalciferol 100 000 IU/g) 200 IU, Vitamin C (from Ascorbic acid 97 %) 34,99 mg, Vitamin B3 (from Nicotinamide) 5 mg, Vitamin B2 (from Riboflavin) 1,2 mg, Vitamin B1 (from Thiamine HCl) 0,79 mg, Vitamin B12 (from Cyanocobalamin 0,1 %) 2,5 µg. Category D Medicine: Health Supplement : D 34.12 Multiple substance formulation This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 GDC Vitamin B Co Syrup 100 mL. Each 5 mL syrup contains: Vitamin B3 (from Nicotinamide) 10 mg, Vitamin B2 (from Riboflavin) 2,5 mg, Vitamin B1 (from Thiamine HCl) 1,57 mg, Vitamin B6 (from Pyridoxine HCl) 0,82 mg, Vitamin B12 (from Cyanocobalamin 0,1 %) 2,5 µg Category D Medicine: Health Supplement : D 34.12 Multiple substance formulation. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Zyora Zymag+ 10s and 30s. Each effervescent tablet contains: Magnesium carbonate 1 090 mg providing Magnesium (elemental) 250 mg, Ascorbic acid (Vitamin C) 200 mg, MecobalActive® as methylcobalamin (Vitamin B12) 50 μg. Category D Medicine: Health Supplement : D 34.12 Multiple substance formulation. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Zyora Zyzinc Effervescent tablets 20s. Each tablet contains the following active materials: Zinc lactate 46,5 mg (providing Zinc 10 mg), Ascorbic Acid 1000 mg (providing Vitamin C 1000 mg) and Cholecalciferol (Vitamin D3) 1000 IU Category D Medicine: Health Supplement : D 34.12 Multiple substance formulation. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Zyora Zyzinc capsules 60s. Each capsule contains: L-methionine Zinc complex 62,5 mg yielding elemental Zinc 12,5 mg, Vitamin C (calcium ascorbate) 500 mg, Cholecalciferol (Vitamin D3) 500 IU Category D Medicine: Health Supplement : D 34.12 Multiple substance formulation. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Zyora Zyboost Effervescent tablets 10s and 30s. Each effervescent tablet contains: Paullinia cupana Kunth (Guarana) 200 mg [seed, extract standardised to 20 % (40 mg) caffeine], Ascorbic acid (Vitamin C) 500 mg, Calcium carbonate 277,8 mg providing Calcium (elemental) 100 mg, Magnesium oxide 169,5 mg providing Magnesium (elemental) 100 mg, Niacinamide (Vitamin B3) 20 mg, Zinc oxide 13,7 mg providing Zinc (elemental) 11 mg, Calcium D-pantothenate 10,9 mg providing Pantothenic acid (Vitamin B5) 10 mg, Pyridoxine HCl 12,3 mg providing Pyridoxine (Vitamin B6) 10 mg, Riboflavin 5-phosphate sodium 6,7 mg providing Riboflavin (Vitamin B2) 5 mg, Thiamine HCl 5,7 mg providing Thiamine (Vitamin B1)  5 mg, Folic acid 200 μg, D-Biotin (Vitamin H) 100 μg, MecobalActive® as methylcobalamin (Vitamin B12) 50 μg Category D Medicine: Health Supplement : D 34.12 Multiple substance formulation. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Zyora ZyB+ capsules 60 capsules. Each delayed release capsule contains: Niacinamide ascorbate 48,5 mg providing Niacin (Vitamin B3) 20 mg, Calcium D-pantothenate 43,5 mg providing Pantothenic acid (Vitamin B5) 20 mg, Riboflavin 5-phosphate sodium 31,8 mg providing Riboflavin (Vitamin B2) 25 mg, Thiamine HCl 31,8 mg providing Thiamine (Vitamin B1) 25 mg, Pyridoxine HCl 24,3 mg, providing Pyridoxine (Vitamin B6) 20 mg, D-alpha-tocopherol (Vitamin E) 5 mg, ExtraFolate-S® (as Methyltetrahydrofolic acid) 400 μg, providing Folate 327 μg, MecobalActive® Methylcobalamin (Vitamin B12) 100 μg, Biotin (Vitamin H) 50 μg Category D Medicine: Health Supplement : D 34.12 Multiple substance formulation. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Zyora Zycalm capsules 30s. Each capsule contains: Valerian extract 100 mg, L-theanine 200 mg Category D Medicine: Discipline Specific : D 33.7 Combination product. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Zyora Zykrill®  30s and 60s. Each capsule contains: Krill oil 590 mg providing phospholipids 330 mg, astaxanthin 50 μg, choline 41 mg, Total Omega-3 159 mg, EPA 89 mg and DHA 41 mg. Category D Medicine: Health Supplement : D 34.2 Fats, Oils and Fatty Acids. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

Women’s health

  • S0 Sinopol Sachets 30s. Each sachet contains: Alpha-lipoic acid 400 mg, Myo-inositol 1000 mg, Folic acid 200 µg. Category D Medicine:  Health Supplement: D 34.13 Other. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S0 Sinopol Tablets 30s. Each tablet contains: Alpha-lipoic acid 400 mg, Myo-inositol 500 mg, Betaine 50 mg, Riboflavin 0,85 mg providing Vitamin B2 0,85 mg, Pyridoxine 0,95 mg providing Vitamin B6 0,95 mg, Folic acid 200 µg, Cyanocobalamin 1,3 µg providing Vitamin B12 1,3 µg. Category D Medicine: Health Supplement: D 34.13 Other. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.

  • S1 Gynezol 50 g. Each 1 g cream contains: Clotrimazole 10 mg. Reg. nr: 28/20.2.2/0418

  • S4 Fertab 10s. Each tablet contains: Clomiphene citrate 50 mg. Reg. nr: 44/18.8/1034

Respiratory & Cough

  • S2 Phenorant 100 mL, 200 mL. Each 5 mL contains: Diphenhydramine HCl 13,33 mg, ammonium chloride 130 mg, sodium citrate 54,166 mg. Ref. nr:  G1054 (Act 101/1965)

  • S2 Phenorant with Codeine 100 mL. Each 5 mL contains: Diphenhydramine HCl 13,33 mg, ammonium chloride 130 mg, sodium citrate 54,166 mg , codeine phosphate 8,33 mg. Ref. nr:  G1053 (Act 101/1965)

  • Iodised Throat Lozenges 20s, 100’s, 1000s. Each lozenge contains: Iodine 0,014 mg, phenol 4,25 mg. Disinfectant

  • S2 Theophylline 300 GDC Each tablet contains: Theophylline 300 mg Ref. nr:  33/10.2/0417

  • S2 Theophylline 200 GDC Each tablet contains: Theophylline 200 mg Ref. nr:  33/10.2/0416

  • S2 Nuelin SA Each tablet contains:Theophylline 250 mg Ref. nr: P/10.2/54

  • S2 Nuelin Liquid Each 5 ml contains:  Theophylline 25 mg Ref. nr: S/10.2/126

Anti-depressants

  • S5 Gulf Amitriptyline 25 100s, 500s. Each tablet contains: Amitriptyline HCl 25 mg. Reg. nr: A40/1.2/0605

Corticosteroids

  • S4 Trolic 5 mg 1000’s. Each tablet contains: Prednisone 5 mg. Ref. nr:  G3093 (Act 101/1965)

Anti-infectives & Anti-microbials

  • S1 Clomaderm 20 g. Each 1 g cream contains: Clotrimazole 10 mg. Reg. nr:  28/20.2.2/0419

  • S4 Gulf Fluconazole 200 mg 28s: Each capsule contains: Fluconazole 200 mg. Reg. nr:  41/20.2.2/0107

  • S2 FLUCONAZOLE 150 GDC  1s. Each capsule contains: Fluconazole 150 mg. Reg. nr: 40/20.2.2/0124

  • S4 Doctrim Suspension 50 mL, 100 mL. Each 5 mL contains: Sulfamethoxazole 200 mg; trimethoprim 40 mg. Reg. nr:  28/20.2/0378

  • S4  Amoxy Co 1000/200 GDC. Each vial contains Amoxicillin sodium equivalent to 1000 mg amoxicillin and potassium clavulanate equivalent to 200 mg clavulanic acid. Reg. nr:  41/20.1.2/0978

  • S4 Amoclan. Each tablet contains Amoxicillin trihydrate equivalent to 250 mg amoxicillin and potassium clavulanate equivalent to 125 mg clavulanic acid. Reg. nr:  35/20.1.2/0232

  • S4 Amoclan Forte. Each tablet contains Amoxicillin trihydrate equivalent to 500 mg amoxicillin and potassium clavulanate equivalent to 125 mg clavulanic acid. Reg. nr:  35/20.1.2/0233

  • S4 Amoclan BID Tablets. Each tablet contains Amoxicillin trihydrate equivalent to 875 mg amoxicillin and potassium clavulanate equivalent to 125 mg clavulanic acid. Reg. nr:  35/20.1.2/0361

  • S4 Amoclan S. Each 5 mL contains Amoxicillin trihydrate equivalent to 125 mg amoxicillin and potassium clavulanate equivalent to 31,25 mg clavulanic acid. Reg. nr:  35/20.1.2/0249

  • S4 Amoclan SF. Each 5 mL contains Amoxicillin trihydrate equivalent to 250 mg amoxicillin and potassium clavulanate equivalent to 62,5 mg clavulanic acid. Reg. nr:  35/20.1.2/0250

  • S4 Amoclan BID. Each 5 mL contains Amoxicillin trihydrate equivalent to 400 mg amoxicillin and potassium clavulanate equivalent to 57 mg clavulanic acid. Reg. nr:  35/20.1.2/0085

Cardio & Hypertension

  • S3 Indoblok 10 1000s. Each tablet contains: Propranolol HCl 10 mg. Reg. nr:  28/5.2/0420

  • S3 Indoblok 40 1000s. Each tablet contains: Propranolol HCl 40 mg. Reg. nr:  28/5.2/0421

  • S3 Amlodipine 5 GDC 30s. Each tablet contains: Amlodipine 5 mg. Reg. nr:  41/8.1/0812

  • S3 Amlodipine 10 GDC 30s. Each tablet contains: Amlodipine 10 mg. Reg. nr:  41/7.1/0813

Other

  • S2 Painblok Cold and Flu (12s, 20s). Each effervescent tablet contains: 2 mg Chlorphenamine maleate, 500 mg Paracetamol and Sodium ascorbate equivalent to 250 mg Vitamin C. Reg. Nr:  49/5.8/0942. Applicant:  Trinity Pharma (Pty) Ltd, 3 Gwen Lane, Fourth Floor, Sandton, 2031. Tel:  010 594 5610. pv@trinity.co.za. Marketed by:  Gulf Drug Company (Pty) Ltd, info@gulfdrug.co.za

  • S0 Bionase Nasal Spray (30 ml & 50 ml). Each 1 ml contains: Sodium chloride 0,72 % m/v, seminose 80 mg, sorbitol 50 mg. Category D Medicine: Health Supplements: D 34.10 Saccharides. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. Applicant: Medicine Developers International Healthcare CC. Marketing & Distribution: Gulf Drug Company (Pty) Ltd. Unit 4B, 61 Marshall Drive, Mount Edgecombe, 4300.For full prescribing details refer to the approved patient information leaflet. Further information is available from Gulf Drug Company (Pty) Ltd. info@gulfdrug.co.za

  • S0 Bionase Nasal Spray Kids (30 ml). Each 1 ml contains: Sodium chloride 0,72 % m/v, seminose 80 mg, sorbitol 50 mg, Category D Medicine: Health Supplements: D 34.10 Saccharides. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. Applicant: Medicine Developers International Healthcare CC. Marketing & Distribution: Gulf Drug Company (Pty) Ltd. Unit 4B, 61 Marshall Drive, Mount Edgecombe, 4300. For full prescribing details refer to the approved patient information leaflet. Further information is available from Gulf Drug Company (Pty) Ltd. info@gulfdrug.co.za

  • S0 Bionase Nasal Gel (30 ml). Each 1 ml contains: Sodium chloride 0,72 % m/v, Aloe barbadensis miller (Aloe vera) 30 % m/v [leaves, providing 0,3 g gel], seminose 33,33 mg, sorbitol 150 mg, zinc oxide 10 mg. Category D Medicine: Health Supplements: D 34.12 Multiple substance formulation. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. Applicant: Medicine Developers International Healthcare CC. Marketing & Distribution: Gulf Drug Company (Pty) Ltd. Unit 4B, 61 Marshall Drive, Mount Edgecombe, 4300. For full prescribing details refer to the approved patient information leaflet. Further information is available from Gulf Drug Company (Pty) Ltd. info@gulfdrug.co.za

  • S0 Bionase Biobact Nasal Cream (10 g). Each 1 ml contains: Seminose 30mg, Zinc Oxide 10 mg, Aloe barbadensis miller (Aloe vera) 10 % m/m [leaves, providing 0,1g gel]. Category D Medicine: Health Supplements: D 34.12 Multiple substance formulation. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use.. Applicant: Medicine Developers International Healthcare CC. Marketing & Distribution: Gulf Drug Company (Pty) Ltd. Unit 4B, 61 Marshall Drive, Mount Edgecombe, 4300. For full prescribing details refer to the approved patient information leaflet. Further information is available from Gulf Drug Company (Pty) Ltd. info@gulfdrug.co.za

  • S0 UTI-X Advanced 8s. Each vegecap contains:  Hibiscus sabdariffa, (Ellirose) 200 mg [flower and calyx], Vaccinium macrocarpon Aiton, fructus (Exocyan Cran 50s) 72 mg [fruit, supplying proanthocyanidins 36 mg], Taraxacum officinale (Dandelion) 200 mg [leaves, 4: 1 extract]. Category D Medicine: Discipline Specific: D33.6 Western Herbal Medicine. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. Applicant: Medicine Developers International Healthcare CC. Marketing & Distribution: Gulf Drug Company (Pty) Ltd. Unit 4B, 61 Marshall Drive, Mount Edgecombe, 4300. For full prescribing details refer to the approved patient information leaflet. Further information is available from Gulf Drug Company (Pty) Ltd. info@gulfdrug.co.za

  • S0 UTI-X Maintenance 28s. Each vegecap contains:  Vaccinium macrocarpon Aiton, fructus (Exocyan Cran 50s) 72 mg [fruit, supplying proanthocyanidins 36 mg], Pyridoxine (Vitamin B6) 50 mg, D-mannose 400 mg. Category D Medicine: Discipline Specific: D33.6 Western Herbal Medicine. This unregistered medicine has not been evaluated by the SAHPRA for its quality, safety or intended use. Applicant: Medicine Developers International Healthcare CC. Marketing & Distribution: Gulf Drug Company (Pty) Ltd. Unit 4B, 61 Marshall Drive, Mount Edgecombe, 4300. For full prescribing details refer to the approved patient information leaflet. Further information is available from Gulf Drug Company (Pty) Ltd. info@gulfdrug.co.za


Marketing references

A.        Magasil 100mL and 200mL

  • Magasil professional information and patient information leaflet.

B.        Painblok (Painblok 10s, 24s, 48 x 2s, 100s, 1000’)

  • Painblok tablets approved professional information.

  • https://www.mayoclinic.org/diseases-conditions/migraine-headache/expert-answers/migraine-headache/faq-20058505.

  • Eccleston, C., Fisher, E., Howard, R. F., Slater, R., Forgeron, P., Palermo, T. M., Birnie, K. A., Anderson, B. J., Chambers, C. T., Crombez, G., Ljungman, G., Jordan, I., Jordan, Z., Roberts, C., Schechter, N., Sieberg, C. B., Tibboel, D., Walker, S. M., Wilkinson, D., & Wood, C. (2021) ‘Delivering transformative action in paediatric pain: a Lancet Child & Adolescent Health Commission’, The Lancet Child & Adolescent Health, 5(1), pp. 47-87. doi:10.1016/S2352-4642(20)30277-7.

  • Freo, U., Ruocco, C., Valerio, A., Scagnol, I., & Nisoli, E. (2021). Paracetamol: A Review of Guideline Recommendations. Journal of Clinical Medicine, 10(15), 3420. https://doi.org/10.3390/jcm10153420

  • Stephens, G., Derry, S. & Moore, R. A. (2016) ‘Paracetamol (acetaminophen) for acute treatment of episodic tension‑type headache in adults’, Cochrane Database of Systematic Reviews, 2016(6), Art. No.: CD011889. doi: 10.1002/14651858.CD011889.pub2.

C.       Painblok (Painblok syrup 50mL & 100ml; Painblok Alcohol sugar free syrup 50mL &100mL)

  • Painblok tablets approved professional information.

  • https://www.mayoclinic.org/diseases-conditions/migraine-headache/expert-answers/migraine-headache/faq-20058505.

  • Eccleston, C., Fisher, E., Howard, R. F., Slater, R., Forgeron, P., Palermo, T. M., Birnie, K. A., Anderson, B. J., Chambers, C. T., Crombez, G., Ljungman, G., Jordan, I., Jordan, Z., Roberts, C., Schechter, N., Sieberg, C. B., Tibboel, D., Walker, S. M., Wilkinson, D., & Wood, C. (2021) ‘Delivering transformative action in paediatric pain: a Lancet Child & Adolescent Health Commission’, The Lancet Child & Adolescent Health, 5(1), pp. 47-87. doi:10.1016/S2352-4642(20)30277-7.

  • Freo, U., Ruocco, C., Valerio, A., Scagnol, I., & Nisoli, E. (2021). Paracetamol: A Review of Guideline Recommendations. Journal of Clinical Medicine, 10(15), 3420. https://doi.org/10.3390/jcm10153420

  • Stephens, G., Derry, S. & Moore, R. A. (2016) ‘Paracetamol (acetaminophen) for acute treatment of episodic tension‑type headache in adults’, Cochrane Database of Systematic Reviews, 2016(6), Art. No.: CD011889. doi: 10.1002/14651858.CD011889.pub2.

  • NHS, Baby teething symptoms, 2022. Date of Access: 30/06/2026. https://www.nhs.uk/baby/babys-development/teething/baby-teething-symptoms/

D.       Sinopol sachets 30s and Sinopol tablets 30s:

  • Sinopol® approved professional information, February 2024.

  • Genazzani AD, Prati A, Marchini F, Petrillo T, Napolitano A, Simoncini T. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. Gynecological Endocrinology 2019. Doi: 10.1080/09513590.2019.1640200.

  • Keen MA, Shah IH, Sheikh G. Cutaneous Manifestations of Polycystic Ovary Syndrome: A Cross-Sectional Clinical Study. Indian Dermatol Online J. 2017;8(2):104–110. doi

  • Bellver J, Rodríguez-Tabernero L, Robles A, Muñoz E, Martínez F, Landeras J. et al. Polycystic ovary syndrome throughout a woman’s life. J Assist Reprod Genet 2018;35:25–39. Doi:10.1007/s10815-017-1047-7.

  • Genazzani AD, Despini G, Santagni S, Prati A, Rattighieri E, Chierchia E, et al. Effects of a Combination of Alpha Lipoic Acid and Myo-Inositol on Insulin Dynamics in Overweight/Obese Patients with PCOS. Endocrinol Metab Synd 2014,3(3). DOI: 10.4172/2161-1017.1000140.   

  • Genazzani AD, Shefer K, Della Casa D, Prati A, Napolitano A, Manzo A, et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest 2018;41:583–590.      

  • Derosa G, D’Angelo A, Romano D, Maffiolo P. A Clinical Trial about a Food Supplement Containing α-Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. Int J Mol Sci 2016;17:1802. doi:10.3390/ijms17111802.

  • Rago R, Marcucci I, Leto G, Caponecchia L, Salacone P, Bonanni P, et al. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study. J Biol Regulators Homeostatic Agents 2015;29(4):1-11.

  • Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2014:6 1–13.

  • Teede HJ, Misso ML, Deeks AA, Moran LJ, Stuckey BGA, Wong JLA, et al. Assessment and Management of polycystic ovary syndrome; summary of an evidence-based guideline. Med J Aust 2011;195(6):S65-S112

  • Carbonelli MG, Di Renzo L, Bigioni M, et al. α-Lipoic Acid Supplementation: A Tool for Obesity Therapy.? Curr Pharmaceut Design 2010;16:840-846.                                                                                                                                                                                              

  • Cappelli V, Musacchio MC, Bulfoni A, Morgante G, De Leo V. Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS. Eur Rev Med Pharmacol Sci 2017; 21(2Suppl):15-29.

  • Günalan E, Yaba A, Yılmaz B. The effect of nutrient supplementation in the management of polycystic ovary syndrome-associated metabolic dysfunctions: A critical review. J TurkGer Gynecol Assoc 2018;19:220-32. Doi: 10.4274/jtgga.2018.0077. 20.

  • Iezzi ML, Varriale G, Rorge N, Lasorella S, Zagaroli L, Verrotti A. Polycystic ovary syndrome in adolescence: new therapeutic approach with inositol and alphalipoic acid. Int J Curr Res 2017;9(7):54006-54011

  • De Cicco S, Immediata V, Romualdi D, et al. Myoinositol combined with alpha-lipoic acid may improve the clinical and endocrine features of polycystic ovary syndrome through an insulin-independent action. Gynecol Endocrinol 2017;33(9):698–701."

  • Mohamaddi M. Oxidative Stress and Polycystic Ovary Syndrome: A Brief Review. Int J Prev Med 2019;10:86. Doi: 10.4103/ijpvm.IJPVM_576_17.

  • Constantino D, Minozzi G, Minozzi F, et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13:105-110

  • Haghighian HK, Haidari F, Mohammadi-asl J, Dadfar M. Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. Fertil Steril 2015;104:318-24.

  • Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Medicine 2010;8:41.

  • Teede H.J., Bahri Khomami M., Morman R., Laven J.S.E., Joham A.E., Costello M.F., Patil M., Rees D.A., Berry L., Cree M.G., Zhao H., Norman R.J., Dokras A. and Piltonen T. et al., 2026. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Published online 12 May 2026. Available at: https://doi.org/10.1016/S0140-6736(26)00717-8

  • Cunha A, Póvoa AM. Infertility management in women with polycystic ovary syndrome: a review. Porto Biomed J. 2021 Jan 26;6(1):e116. doi: 10.1097/j.pbj.0000000000000116. PMID: 33532657; PMCID: PMC7846416.

  • Regidor, P.-A., Schindler, A.E., Lesoine, B. and Druckman, R., 2018. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature. Hormone Molecular Biology and Clinical Investigation, 34(2), p.20170067. Available at: https://doi.org/10.1515/hmbci-2017-0067

E.        Zyora zyboost™ effervescent tablets 10s and 30s:

F.         Zyora zymag™ effervescent tablets 10s and 30s:

  • Zymag approved professional information.

  • Tarsitano, M.G., Quinzi, F., Folino, K., Greco, F., Pio Oranges, F., Cerulli, C., and Emerenziani, G.P. Effects of magnesium supplementation on muscle soreness in different types* of physical activities: a systematic review. Journal of Translational Medicine (2024) 22:629.

  • Reno AM, Green M, Killen LG, O’Neal EK, Pritchett K, et al. Effects of magnesium supplementation on muscle soreness and performance.

  • Strength Cond Res. 2022;36(8):2198–203. https:// doi. org/ 10. 1519/ JSC.

  • Steward CJ, Zhou Y, Keane G, Cook MD, Liu Y, et al. One week of magnesium supplementation lowers IL-6, muscle soreness and increases post-exercise blood glucose in response to downhill running. Eur J Appl Physiol. 2019;119(11–12):2617–27. https:// doi. org/ 10. 1007/ s00421- 019- 04238-y.

  • MecobalActive Provides Sustainable Solution for Vitamin B12 Supplements to Reduce Pollution Impact on Earth. https://www.globenewswire.com/news-release/2019/12/09/1958087/0/en/MecobalActive-Provides-Sustainable-Solution-for-Vitamin-B12-Supplements-to-Reduce-Pollution-Impact-on-Earth.html Date of access: 04/10/2024

G.      Zyora zyzinc™ capsules 60s:

  • Zyora zyzinc™ capsules approved professional information.

  • Read, A.R et al. The Role of Zinc in Antiviral Immunity. Adv Nutr 2019; 10:696 - 710.

  • Chien, X.X., Zafra-Stone, S., Bagchi, M., Debasis, B. 2006. Bioavailability, antioxidant and immune-enhancing properties of zinc methionine. BioFactors, vol. 27, no. 1-4, pp. 231-244, 2006.

H.      Zyora zyzinc™ effervescent tablets 20s:

  • Zyora zyzinc™ effervescent tablet approved professional information.

  • Read, A.R et al. The Role of Zinc in Antiviral Immunity. Adv Nutr 2019; 10:696 - 710.

  • Chien, X.X., Zafra-Stone, S., Bagchi, M., Debasis, B. 2006. Bioavailability, antioxidant and immune-enhancing properties of zinc methionine. BioFactors, vol. 27, no. 1-4, pp. 231-244, 2006.

I.        Zyora zycalm™ 30 capsules

  • Zyora zycalm™ approved professional information.

  • Baba, Y., Inagaki, S., Nakagawa, S., Kaneko, T., Kobayashi, M.  and Takihara, T. 2021. Effects of l-Theanine on Cognitive Function in Middle-Aged and Older Subjects: A Randomized Placebo-Controlled Study. J Med Food. April 2021; 24(4): 333–341.

  • Hidese, S., Ogawa, S., Ota, M., Ishida, I., Yasukawa, Z., Ozeki, M., and Kunugi, H. 2019. Effects of L-Theanine Administration on Stress-Related Symptoms and Cognitive Functions in Healthy Adults: A Randomized Controlled Trial. Nutrients. 2019 Oct; 11(10): 2362.

  • Roh, D., Jung, J.H., Yoon, K.H., Lee, C.H., Kang, L.Y., Lee, S., Shin, K., Kim, D.H. 2019. Valerian extract alters functional brain connectivity: A randomized double-blind placebo-controlled trial.  Phytotherapy research: Volume33, Issue 4, April 2019 Pages 939-948.

J. De Witts Tablets

  • Skosana, B., Aboua, G. & du Plessis, S. S. (2014) ‘Buchu – The Multi‑Purpose Ethnomedicinally Important Specie and Its Benefits in the Reproductive System’, in Oguntibeju, O. (ed.) Antioxidant‑Antidiabetic Agents and Human Health. Rijeka: InTech, pp. 297. doi:10.5772/57233.

  • Skosana, B., Aboua, G. & du Plessis, S. S. (2014) ‘Buchu – The Multi‑Purpose Ethnomedicinally Important Specie and Its Benefits in the Reproductive System’, in Oguntibeju, O. (ed.) Antioxidant‑Antidiabetic Agents and Human Health. Rijeka: InTech, pp. 298. doi:10.5772/57233.

  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Buchu. [Updated 2023 Mar 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK589899/

K. Fyberlax

  • National Institute on Aging, 2005. Concerned about Constipation?. U.S. Department of Health and Human Services, National Institutes of Health. University of Minnesota. pp.5.